Post by
antigua1987 on Aug 23, 2021 8:46am
Pfizer buys out Trillium, mkt val 2.2B US, 18.50US SP...
Trillium at similiar ops stage as IMV's MVP-s in I/O, w phase 1/2 vax, no revenues, steadily declining SP over last 60 mons.
Differences - dpx is delivery vehicle able to expand product line, Trillium is all vax. And Pfizer already had a piece of Trillium, and a director on BoD.
Though looks great from here with IMV @1.60US, would be disappointing if that's all to look forward to.